Impact Factor 5.511
2017 JCR, Clarivate Analytics 2018

Among the world's top 10 most-cited Immunology journals

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.01196

Immunomodulation in primary immune thrombocytopenia: a possible role of the Fc fragment of romiplostim?

  • 1Universitätskinderklinik Basel, Switzerland

Fc fusion proteins and Fc fusion peptides or peptibodies are chimeric molecules composed of an active pharmacological protein or peptide and the Fc fragment of an immunoglobulin. The primary aim of this drug construct is to prolong the half-life of the active component. This molecular architecture is seen in drugs, such as etanercept, romiplostim and the recombinant factor VIII (efmoroctocog alfa). A considerable number of Fc fusion proteins and peptibodies are currently in preclinical and clinical development. The isolated effect of the Fc fragment has been studied intensively during last years, but is still poorly understood in the clinical setting and in relation with the active drug and underlying disease. In this short review, we will propose new hypotheses of possible immunomodulatory functions of the Fc fragment of romiplostim in patients with primary immune thrombocytopenia.

Keywords: ITP (Idiopathic Thrombocytopenic Purpura), Immunomodulation agents, thrombopoietin receptor agonists(TPO-RA), Fc-Fragment, Peptibody, romiplostim, Fc fusion protein

Received: 22 Mar 2019; Accepted: 13 May 2019.

Edited by:

David W. Scott, Uniformed Services University of the Health Sciences, United States

Reviewed by:

Cindy Neunert, Columbia University, United States
John W. Semple, Lund University, Sweden  

Copyright: © 2019 Schifferli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Alexandra Schifferli, Universitätskinderklinik Basel, Basel, Switzerland, alexandra.schifferli@ukbb.ch